Adamax is a market name, not a registry entry. As of September 23, 2026 there is no PubChem record for it, no CAS Registry Number a public resolver will return, and no peer-reviewed pharmacology: every PubMed hit for the word is a machine-learning optimiser sharing the name. This article records which searches were run and what each returned, so a reader can repeat them, and why a structure is attributed to a name no registry holds.

The searches, and what each one returned

One limit on the CAS line. CAS Common Chemistry is gated behind an API key, so that negative rests on the NCI resolver plus PubChem holding no CAS-bearing synonym: corroborated rather than absolute. CAS Registry Number, UNII and InChIKey are defined in our paperwork glossary.

Every PubMed hit is an optimiser, not a molecule

The bare term returns 39 records. A spot check of twelve titles finds a convolutional-network study on potato leaf disease (PMID 42151246) and a comparison of machine-learning models for nanofluid viscosity (PMID 32906742): in that literature Adamax is a gradient-descent optimiser used to train neural networks. Constrained to titles and abstracts alongside the word peptide, the corpus shrinks to one 2026 Diabetes Obes Metab paper, the optimiser again. "Adamax studies" and "adamax research" are searches for a literature that does not exist.

The structure commonly attributed to Adamax

Exactly one public source publishes a structure with identifiers attached, and it is tertiary: the English Wikipedia entry. It gives the shorthand Ac-MEHFPGP^A G-NH2, the formula C50H69N11O11S, the InChIKey SWAHDDQBIQRRFH-MHNCVWKMSA-N and a SMILES string, calling the compound a designer analogue of semax with the terminal modifications found in Peptide 021.

Reading that SMILES: an acetyl cap on the N-terminus, the semax heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro in the middle, the C-terminal proline carboxyl converted to an amide with 3-carbamoyl-adamantan-1-ylamine.

PubChem holds neither the name nor that InChIKey, and an encyclopedia entry is not a synthesis paper, a supplier specification or a regulatory filing. The accurate phrasing is "the structure commonly attributed to Adamax".

Where the number 1032 comes from

Computed at standard atomic weights, C50H69N11O11S has an average mass of about 1032.2. That is the number people type when they search "adamax 1032" or "adamax vs adamax 1032". The same query data shows "adamax with adamantane" run against "adamax without adamantane".

Those searches say something plain: material is sold under one name that is not one molecule, and buyers can tell. A name with no registry entry cannot settle it, because there is no identifier against which two vials can be compared. Two names can therefore look like two products when nothing public separates them.

The adamantyl cap belongs to a different peptide's literature

The cap in that attributed structure is chemically the same one carried by Peptide 021, or P021: PubChem CID 56589645, C27H42N6O8, average mass 578.7, structurally Ac-Asp-Gly-Gly-Leu-NH-(3-carbamoyl-1-adamantyl). P021 derives from ciliary neurotrophic factor, not ACTH, and the published rationale for the adamantyl group is stated once, for it.

"Peptide 021 (P021) is a neurotrophic/neurogenic tetra-peptide that was derived from the most active region of the ciliary neurotrophic factor (CNTF) by epitope mapping. Admantylated glycine was added to its C-terminal to increase its blood-brain barrier permeability and decrease its degradation by exopeptidases to make it druggable."Baazaoui N, Iqbal K, *Alzheimer's Research & Therapy*, 2017 (PMID 28655344)

Citing that paper as evidence about Adamax is a category error. The two share a terminal cap and nothing else: P021 is a four-residue neurotrophic-factor fragment, the structure attributed to Adamax a seven-residue ACTH-derived backbone. No study has tested whether the cap's chemistry carries across, and PubMed returns zero records for adamantane and semax.

What a documented molecule looks like next to it

Noopept is not an adamantane compound and has no structural relationship to semax. It is a dipeptide-derived ester, N-phenylacetyl-L-prolylglycine ethyl ester, so "adamantane-modified noopept" is wrong on both halves. Semax's own chemistry and US status are covered in Semax and Selank. One registered neighbour is worth naming, since vendors describe Adamax as an analogue of it: N-acetyl semax amidate, PubChem CID 172638603, CAS 2920938-90-3, average mass 855.0.

The one government document that names Adamax

New Zealand's Medsafe published "Classification of Unscheduled Peptides" in June 2025, for the 74th meeting of the Medicines Classification Committee. It names Adamax once, proposing a group entry.

"This class would encompass any analogues of ACTH, such as Adamax and Semax (two peptide products currently marketed as cognitive enhancers). It would capture any new/novel products with a similar chemical structure."Medsafe, Classification of Unscheduled Peptides, June 2025

The document recommends that ACTH analogues be classified as a group entry, and individually as new substances arise, as prescription medicines. Three things about it. It is a New Zealand proposal, not a United States action. It classifies Adamax by claimed lineage and states no structure, formula or CAS number, so it is evidence the name is in trade, not chemical evidence. And whether the committee adopted it is unverified; no minutes or decision are published.

US regulatory footprint: none at all

As of September 23, 2026 the Federal Register API returns count 0 for conditions[term]=adamax, and FDA's warning-letter full-text index returns 0 records for the same word. There is no FDA-approved product containing it and no USP or NF monograph, and it is absent from FDA's April 16, 2026 Federal Register notice for the Pharmacy Compounding Advisory Committee, which lists BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon.

Noopept, by contrast, has a US footprint: an FDA warning letter to Crystal Clear Supplements dated February 4, 2022, citing sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act, and two final debarment orders published on January 20, 2023 that name noopept crystalline powder among nootropic products a debarred pair imported and redistributed as supplements.

Adamax has none of that as of September 23, 2026, which is neither good nor bad news: it means no US regulator has addressed the name, so nothing about it has been decided either way.

What to expect on a certificate for a compound with no CAS number

A certificate for a registered substance can be checked against the registry: CAS number, UNII and formula must agree with a public record. For a name with no registry entry that check is unavailable, and a certificate printing a CAS number for Adamax prints something no resolver confirms.

What stays checkable is everything not depending on a registry: the structure the laboratory says it assayed, written out in full rather than named; the measured mass against the mass computed from that structure; chromatographic purity with the method stated; net peptide content, separately from purity; and the laboratory's accreditation. How to run those checks is in checking a peptide lab report.

We list Adamax as a lyophilized vial and the Adamax liquid spray as a 10 mL solution, and publish no CAS number or PubChem CID for either, because there is none to publish.

Sources

• NCI/NIH CACTUS chemical identifier resolver, National Cancer Institute
• Semax, CID 9811102, PubChem
• Noopept (omberacetam), CID 180496, PubChem
• Peptide 021, CID 56589645, PubChem
• N-acetyl semax amidate, CID 172638603, PubChem
• Baazaoui N, Iqbal K, Alzheimer's Research and Therapy, 2017, PMID 28655344
• FDA briefing document on semax, Pharmacy Compounding Advisory Committee, 2026
• Federal Register notice 2026-07361, 91 FR 20465, April 16, 2026, GovInfo
• Warning letter to Crystal Clear Supplements, FDA, February 4, 2022
• Final Debarment Order, FR Doc 2023-00999, January 20, 2023, GovInfo
• Classification of Unscheduled Peptides, Medsafe New Zealand, June 2025
• Adamax, English Wikipedia (tertiary source; the structure it gives is unverified against any registry)